Shahnaz Miri, MD
Neurology · San Francisco, CANPI 1043605397
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.3%), travel and lodging and education — rather than concentrated in one kind of arrangement. Medtronic accounts for 70.8% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $2,003 and has fallen 87.0% since, to $260 in 2023.
Across 35 payments — averaging $76.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Neurelis, Inc.$276
- Teva Pharmaceuticals USA, Inc.$131
- SK Life Science, Inc.$119
- Boston Scientific$107
- Adamas Pharmaceuticals, Inc.$63
- plus $82 from 2 others
What the payments were for
- Travel & lodging$1,07240%
- Food & beverage$1,52957%
- Education$703%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 23 | $1,892 |
| Neurelis, Inc. | 2 | $276 |
| Teva Pharmaceuticals USA, Inc. | 1 | $131 |
| SK Life Science, Inc. | 1 | $119 |
| Boston Scientific | 1 | $107 |
| Adamas Pharmaceuticals, Inc. | 4 | $63 |
| Amgen | 1 | $50 |
| Avanir Pharmaceuticals, Inc. | 2 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,670 in reported general payments places this provider in the 60th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 27 | $147,462 |
| Rivastigmine | 12 | $4,145 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 62 | $3,163 |
| Levetiracetam | 39 | $1,518 |
| Gabapentin | 64 | $879 |
| AmantadineAmantadine Hcl | 12 | $555 |
| Baclofen | 24 | $387 |
| Memantine Hcl | 20 | $331 |
| Primidone | 13 | $324 |
| Duloxetine Hcl | 13 | $273 |
| Donepezil Hcl | 14 | $226 |
Paid to pharmacies, not to this prescriber.
Other neurology in San Francisco
- S Claiborne JohnstonSan Francisco$576K
- Armen MoughamianSan Francisco$554K
- Scott ZamvilSan Francisco$447K
- Bruce CreeSan Francisco$412K
- Kenneth LaxerSan Francisco$379K
- Jonathan KatzSan Francisco$294K
- Nada HindiyehSan Francisco$268K
- Douglas GoodinSan Francisco$227K
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.